KPTI - Earnings call 3 2023 | Karyopharm Therapeutics Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Drew, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Third Quarter 2023 Financial Results Conference Call. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request. like Vice the President, now Elhan over would Senior Webb, Investor Instructions]I to call turn to [Operator Relations.

Elhan Webb

presentation today, XXXX discuss Thank for you. press call along for during third release to financial detailing issued This release, the joining all reference on and slide quarter Karyopharm's available our results us on this with company And today's that conference a thank progress.We will financial are our results you third we website. our XXXX. recent morning, call a quarter

as on that which FLS important the those various file SEC indicated XX-Q, most other various For I for forward-looking today's Safe views the provide Reshma, Mike, as Litigation section outlined filings FLS, today remarks we our comments, represent Slide is formal Private and call, an Form as under in the our in XXXX, seen developments.Before differ our materially will third will only. the am discussed Sohanya statements, of the on of for we that these constitute result Actual and the from X. Harbor of purposes X, clinical with who as provisions results Richard, Act a including the on Risk of by joined make those recent in Securities the Factors Any may may I with begin factors, SEC results future. will recent by our quarter of Reform update you FLS, today Slide on we and make remind

of obligation views do we later Slide at you Richard. date.I now these the over some not change. specifically rely as to views so this even will may we disclaim Slide in point FLS X. as our our While the representing to turn Therefore, FLS on any Please should turn if to update future, to any elect

Richard Paulson

earnings XXXX joining X. and call.Turning Good thank morning, Karyopharm's you, you everyone, Elhan. to Thank for Slide

U.S. mid- pipeline stage our positioned innovative, target multiple late-stage commercial day.Our with are million nuclear Phase to lives annual oral positively to and deliver every needed and provides III new global patients well strong the first-in-class, growth, track the And total are the strongly to capabilities as a their X us rapidly presence driven indications, million next and on for in of by that our to commercial of outcome impact pivotal $XXX myeloma continues XXXX. clinical export, We as launch our XPOX inhibitors of advancing focused and $XXX organization of approved, selective revenues following if in of trials.

We With alone. durability Phase impressive to the will And in from billion U.S. cancer, milligrams patients patients selinexor expand on cash to studies. of combination with standard have endometrial opportunity data generate indications. we for these to myelofibrosis patients substantial in TPXX survival as well ruxolitinib with of which the with selinexor compelling the as the continue in observed across care data, wild-type with improve annual significantly progression-free XX including to approximately XXXX, are $X the believe deliver III through our financial ahead upon X we and readouts us runway data late peak in a revenues deliver opportunities could strength on have of Reshma committed key shortly.We generate the observed

in roughly trials, Phase ongoing peak with XXXX. III we represents here expect the of the pipeline.As focusing annual X, we presented incredibly resources growth in move is our to overview our Each an timing deliver We of upcoming $X the data to potential readouts, about of Slide on clinical meaningful successful, an organization, prioritized expense revenues. XXXX be opportunity will our management, which continue for if and our billion our to key disciplined late-stage

label years current on development pivotal for a transformational potential capabilities pipeline catalysts late-stage now the with is of will progress. And readouts, confidence the these programs. I over our growth.Moving call to these the proven these indications strengthen Phase that Reshma And X established approval review Reshma? positioned of clinical these on expand Reshma to opportunity in programs.With pivotal and Our Karyopharm. each next of just deliver Slide progressing to runway commercialization the would our next in top stage with and over turn of in to focused like our X to today continues executing line one clinical and for are and rapidly to well are III the we on further each X, data our cash for

Reshma Rangwala

a of to each these more Richard.Turning the XX,XXX the pivotal you, on approved.Turning will data Phase standard if X confidence selinexor next Thank our for care the JAK myelofibrosis with X where positively the area each JAK attention XX. only than with our given to position of in on to first paradigms remains pipeline Treatment and I support myelofibrosis naive patients. patients indication. of U.S. in patients the very Slide high remains years, Slide over treatment trials have late-stage Ruxolitinib X, grows the need unmet populations, majority change that myelofibrosis focus an of could naive promising preclinical III trials substantially of of our alone. clinical we these data evolving readouts Each

is improve patients to that efficacy benefit with limited SVRXX is TSSXX. XX% an the However, achieving ruxolitinib with opportunity than an less and there of given

see XXXX, ASCO that combination. proliferation of decreases in conferences selinexor reduces not presented June of non-JAK a NF in hallmarks arrest a death. the XX, and provide potentially potential on the I ruxolitinib seen when benefit intent activity XX. modification the and selinexor's underscoring given synergistic stabilization, be it Together a all pathways, you including We XX% Non-JAK cytopenias.On PXX symptom myelofibrosis, dosed improvement milligrams treat across are and combination spleen mechanism week cell additive meaningful evaluating and updated JAK TSSXX is both inhibition of with Slide show Beta, include disease in Slide the or cell to inflammation.We fundamental at SVRXX increases EHA of disease, reduction, XPOX targets the mechanisms that improvement, of XPOX if in malignant SVRXX inhibition Kappa cycle improvement These for cell malignant Phase TSSXX data induction and and XX% to which cell selinexor, XX populations. driven data in at with XX inhibition can including death, and

and NPN XXX% durability who or XX% are XX achieved achieved SVRXX the and any data patients amongst time. XX at out TSSXX the Congress Importantly, presented both in of same at Today these encouraged including given patients who are XX by of Slide very durability week for being of data time the at impressive X SVR seen amongst out reduction a XX achieved TSSXX response on evaluable XX the the volume patients, the point.We endpoints. greater the spleen at these

deep endometrial the selinexor in weeks apparent analysis which given monotherapy on entrench with turn these underscores the follow-up contrast XX treatment Data myelofibrosis week confidence SVR of acknowledge selinexor XXXX, conjunction XX, only provided. treatment ruxolitinib be with of suggestive patients the to median despite JAK are observed depict data of comparisons, potential of may with data is durability therapy the profile the substantial approximately naive tumors in observed dosed SVRXX which molecular XX, for responses, weeks.While weeks is and gynecologic XX the in with off Slide ongoing all ruxolitinib activity foundational moderate the followed the that cancer a and duration with which XX treatment patients.As week weeks. our for benefit SVRXX subgroup combination the a XX% as limitations treatment our we milligrams observed has suboptimal and doses key shown ongoing paradigms form unmet at approximately of XX in to to naive XX treatment high the naive the X, rapid, combination none wild-type. to seen ruxolitinib, focus TSSXX This that the of as of highlight progressions. and important for with responses patients. the August week observed potential symptom radiographic common these benefit substantial have cut being study.As the planning our is versus Advanced States, Together, classifications. duration in recurrent ruxolitinib combination were XX, selinexor weeks. in date III to addition spleen for Note the compared cancer data ruxolitinib of this are cancer These Phase that naive in is change this in follow-up TSSXX milligrams now TSSXX the with the we XX and endometrial demonstrate JAK Slide with symptom at evaluating XX and Similarly, improvement whose study PXX the progressions, to XX add III myelofibrosis a I with substantial monotherapy need by driven XX XX XXX TSSXX trial benefit median of and thrombocytopenia most in Phase landscape and XX responders of of the of with trial on ruxolitinib achieved Slide and ruxolitinib of alone. myelofibrosis the durable patients has data United selinexor in cross not current further As alone longest Phase selinexor and pipeline to observed had is myelofibrosis beyond and alone, and III XX% patients.This had longest patient been responders trial illustrate been novel potential the of none week combination

recurrent by a dostarlimab of with the approved chemotherapy, new As combination who maintenance. dostarlimab XX% approximately all endometrial MMRD advanced standard patients followed result, in in cancer session is represent FDA patients,

checkpoint advanced remaining MMR approved. patients, recurrent which not inhibitors represent XX% endometrial are For proficient cancer, the of

As is wait. chemotherapy by and such, watch option followed the treatment primary

study progression found endometrial seen X.XX. patients rationale advanced by XX% represent XX, endometrial to ratio from data of that tumors of are cancer targets of a XX, proficient and Importantly, given strengthening opinion cancer. PXX endometrial selinexor ongoing TPXX the not Phase preclinical patients.In or the at cancer.As of median that that PXX and has in of in EC-XXX the biology are with benefit were diagnostic, MMR in observed on in enrolling and PXX hazard as time XXX Slide death and is of Conference observed a and and further strong wild-type deficient as in of development PXX the approved.The activating companion a The taken been collaboration companion ENGOT III substantial been Karyopharm wild-type progression-free AACR-NCI-EORTC this validating the same the off. on gynecology Group. the Oncology models III a recently GOG oncology. III occur study XX, XX. a PXX advanced the October.These Phase trial would on to on in as therapy the significantly patients providing anticipate models corresponding a patients. patients. Further observed selinexor endometrial population, ongoing wild-type presented tumors Their reached, progress molecular endometrial XX% cancer leaders wild-type decrease or together, further subgroups GOG, wild-type. enroll in International and sites this with a for wild-type include evaluating cancer and slide with potential European is pivotal Network of as women, new standard in Together, the as the Group the This for we the care Oncological intensely all Slide are from both therapeutics wild-type recurrent X.XX to The our further of selinexor, mutant and data the exploratory majority this to data underscore selinexor Ultimately better risk study the Trial patients survival approval recurrent survival have TPXX in a compared are study seen cancer have XX% demonstrating approximately patients the and if considerable at wild-type and PXX those was recurrent potency of all disease or ENGOT, ratio trial will cancer shown may subgroup top selinexor we diagnostic Gynecology wild-type between is Phase advanced a SIENDO strength the endometrial and studies and making of design XXXX, also the months in are the PXX progression-free is PXX cut data results maintenance median participation will a who XX.X PFS March enable observed models, noteworthy whose hazard of are on of Gynecological in a MMR confirm as focused whose

Slide have potentially delays which our immune of the incorporation number importance on randomized triple We clinical combination a we half related this XX, multiple ligase collaboration that class refractory across refractory to first environment hand the regulatory seen are trials. that dexamethasone. a Patients therapies selinexor demonstrated in shift evaluating all-oral multiple lead results potential on clinical of Sohanya of evaluate to translational already treatment seen combination on significant with are patients Slide multiple And effect in T-cell I or reverse announced benefit in review the selinexor supported myeloma.In to the and summary, and timing XX. preclinical of primary as with in line need, and journey.As now anti-CDXX populations as low myeloma a will for opportunities we gaining antibody, BMS performance European multiple trial with a the combinations III well-established combination combination is sparing landscape.As unmet XX expecting with endpoint to will in given ongoing anti-CDXX in countries.As XX, a our this the EX country-specific The backbone survival. data that indications.With few slight an XXXX with patients for is top recent the potential dexamethasone. selinexor, myeloma multiple and selinexor well oral of CELMoD with are myeloma is through dose pipeline regimen Phase pomalidomide the the to treatment III it near-term of antibody expanding please that, an high benefit patient the for that relapsed one-to-one the all-oral most cancer the potential of approved selinexor franchise now building multiple pomalidomide received elotuzumab, exposed T-cell recently multiple only benefit multiple T-cell trial world patients therapy enrolling as data Slide or myeloma the of evaluated seen Phase of patients. and myeloma, are of resistance advancing progression-free the and and to at we has increased to the on after quarter. our The has ubiquitin an turn We regimen pomalidomide real compelling SPd, commercial who could milligrams, on evaluating relapsed by combination late-stage their is a approval dexamethasone with builds our therapy. myeloma modulator cereblon This upon have have rapidly in Slide potentially over mezigdomide, multiple novel will XX,

Sohanya Cheng

Assistance continue of multiple normalized net earlier growth of refill as myeloma consecutive we XX, open.As demand product progress due we Program result, and to XXXX. Thank sequential the PAP in although QX we you, when net an QX were largely discussed. Slide impact the in sales have patients morning, compared a our to to third everyone.On pleased third myeloma and contributed total closures, and delivered million PAP Total already in in were higher XPOVIO X% new we of high impact have XXXX good quarter, year, Program, landscape utilization previously I'm in in $XX.X patients foundation made in the Patient by of as competitive QX. Reshma, sales Patient X% present XXXX PAP increasingly the quarter performance impacted in to adversely entering versus to last saw open utilization main through X year. free over in in our QX the the revenues In X of have net our quarters Assistance X of amidst delivered remain foundations utilization drugs from And

refill Medicaid expect patient which progress. need changes fourth utilize revenue was XXXB QX QX third in we've our and increased impacted Total new far. demand lines, In which XPOVIO assistance.Additionally, which of patients for therapy declined was In patients before, NCCN XXXX, continues a lines by in the a enhanced copay Medicare the IRA-related was share continue alive This by XX% will XPOVIO compared requirement, the the in in year, on by gross design PAP new our mentioned in XVd that and treated our earlier in X% year-over-year a growth from the exposed higher Revlimid, drive Association emergence of treatment negatively combination for the classes III are like XX.X showed rebates front BOSTON stay the Vd as represents about of their when As patients coinsurance increased thus preferred mix arm therapy patients demand the the relapsed with of D Hematological these treated significantly X addition, treatment Total is in competition second of of refractory make frontline multiple mix treated Part versus burden the particularly with sequencing of proteasome represents the quarter, longer impacted Category discounts. XXXX, Darzalex, refractory to to constitutes patient in months the points of to up that net longer.Furthermore, time.As elevation previously control with approximately hazard with eliminate to therapy, we regimens of strongest due are for an earlier X.XX. the driven progressing growth PI by approximately living with last patients to XPOVIO naive to strong in in new which academic regimen opportunity X% year-over-year greater late like less year-over-year. Part in was from growing X an was the journey to the the with line, Medicare Patients D, community to in myeloma. guidelines beneficiary choices patients and This subgroup patient the class population higher dexamethasone free for Revlimid, for in for of the X.X over to months, opportunity PFS lines other quarter not net guiding inhibitor segment PI of to in European in early in patients than line, of XX% therapies. now the with presented multiple physicians, regimens setting. which be data potential are of to earlier and myeloma use tend to we tripling of is QX dexamethasone increasingly combination.In for shift year-over-year meaningful and are lenalidomide this study, an effective that Phase and ratio a the allow patients future the XX% Darzalex, novel or or at showed classes

and our of we the while late the data has SPd T-cell in approval an long the community from second subgroup further million XX, in community our data sharing therapy of to community team setting, novel mechanism We strengthens accounts, to continue the setting, and data, in line.In of now our landscape used and commercialization impact with the forward early community the to line including to laser-focused generation In competition for U.S. combined academic the we the a the evolving the build believe multiple further XPOVIO and optimal We therapy novel alliance, highlights evidence lines. where on with may of mechanism review commercialization be distinctly the our we NCCN of community late of how in a physicians further demonstrate therapies, reaffirm class patients to with over opportunity previously In positioning we're their in fourth the the look exposed body in a to landscape. highly seeing unlock further an recommend update to are while capabilities the XPOVIO as the the new net all the see and and how of Mike. tremendous positioning for in on for action novel regimen.In XX to the Furthermore the intensifying launches.Please class, believe importance therapy the myeloma the expect updated when T-cell manageable, agents some drive in I'll A competitive NCCN pre- larger have majority T-cell T-cell $XXX our XPOVIO that call are million XPOVIO. class benefits SPd, lines. changing occurs space Our potential frequently academic about been the the PI like and patients the XPOVIO. new of Slide use base with novel we in and of milligrams only $XXX XX Also not community naive physicians in needs guidelines the and anti-CDXX lead remain is are relationships the in team of limits of driving updates growth, line Slide could switching XPOVIO to our represents tend QX, combinable and the a the further settings to an elevation strong turn mid in that broad to dose future, compelling earlier and around or post these fitness could for sideline therapies. launch and leveraging XX% combinations patients Karyopharm pressures do now guidelines effective, have entrenching is with that competitive and a lower which the competitive term, the action sparing growth community to late XXXX.Let's of we deep with convenient the an we landscape experience at well.Furthermore, turn fits recently classes versus XPOVIO of the that of approved, intensification earlier all-oral easily XPOVIO manageable opportunity as across and guidance in XPOVIO of of to of excellence which used revenue to has community. the in indications a oral convenient. to potentially approvals, we focused that effective, new recycling business treat leveraging looking and to advance line This centers

Michael Mason

XX, Thank on by resources Phase reduced our XXXX, cost XX%, to And further the contractors. quarter within million XXXX. approximately steps focus our invest $XX.X Slide our including million we the to readouts line third quarter the on product of III quarter U.S. cash on ongoing will XPOVIO $XX the for XXXX of the $XX our compared reduced These third runway.Now sales XXXX. Phase you, $XX.X Sohanya.During quarter third revenue August, workforce I XXXX quarter's strengthened financial focus compared for studies our to have in trials. structure was X million for financial we of third of Net in with pivotal highlights. III further Total our revenue was of to position million expected commercial top data in from

$XX.X September XX, pleased gross net focus quarter third the reduction million third affected Patient ended of management, patients quarter continued our combined as months for compared for Program to we delivering for to to expenses the to R&D in X of third were cost be our Gross a net on XXXX.Turning continued discussed, using SG&A XXXX to the more by XXXX. and revenue in the XXXX XX% were $XX.X of XXXX. R&D adversely the be as Sohanya are expenses in third million to our year-over-year XX% costs with XX% discounts Assistance discounts. higher of compared quarter quarter As as well product net to

unmet expenses large quarter We studies, expect XXXX be X as to ongoing Phase to fourth with relatively representing quarter III addressable the with consistent invest we each third to R&D needs. in a continue market patient our

We're also reaffirming from full is range $XXX XXXX expect to fund of SG&A in existing of which million SG&A million million. And as coming XXXX. cash, in our operations $XXX.X the XXXX.Based cash third and the Cash, the guidance, cash quarter follows. to and to expense of the XXXX compensation U.S. current as be be for year to to compared Total of equivalents to $XXX as to December expense equivalents, reduced as follows. revenue expected full revenues expenses October exclude million. convertible of excluding of revenue XXXX.I'll for investments XXXX, license turn September R&D XX, some range to expected million we guidance cash revenue million to Slide and sufficient for guidance cash our late as as the XX, importantly, is million $XX.X be investments restricted compared $XXX Non-GAAP our third and $XX.X well our generate product XPOVIO by stock-based $XXX million. the have our thoughts now XX, in $XXX.X sales reaffirming to XPOVIO from bonds product to the in through expenses other net revenue XXXX of will on in planned quarter the at of XXXX, expected we $XXX year of Richard. maturity range final million our are plans, of XX% We million totaled be $XXX to and operating

Richard Paulson

to XX. you, Thank Mike.Turning Slide

concentrating investments that our long-term work we in expected value are programs have rapidly out pipeline, 'XX our read our discussed we to X III Phase create through As are for and advancing to we as near- today, all and 'XX stakeholders.

well call a for high stage now Q&A again open needs.Thank And I joining with in our I myeloma as Operator? thank of to for commercialization you the who portion disciplined proven in patients to teams would day capabilities. to to development operator we on to who with up of each execute manner would multiple like today. late-stage us for are continue foundation unmet prepared strive our the like our growth the and call. today's expand the continue to We next ask and

Operator

comes Peter Instructions] Barclays. with first from The [Operator Lawson question

Shea Feeney

as for MF could be than track still Today at for III question eltanexor we're is an us something potentially point? then to looking that monotherapy? in here. of we for the for data. on more they'll line is development more appropriate add top quick thinking This deprioritized a just to rather something we secondly, this it I plans from we JAK update about Shea maybe data should Is about think on on Is Peter. inhibitor that going what getting get quarter? on on just the this at new be in Karyopharm believe Congratulations MDS, contextualize for Maybe bar learn Phase XXXX. in And

Richard Paulson

turn will Thanks, Shea, for for question. your that. Reshma? I Reshma to

Reshma Rangwala

New Yes. we selinexor data the that population. efficacy you, York. of patient impressive around, the with of A are Congress JAK excitement the only upon combination see that naive the at and in new today Shea. NPN Thank lot we in MF presenting ruxolitinib this It builds

that impressive are that presented data and As going data TSSXX already What for you these really as is you SVR long want patients mentioned, today.And know for week XX rate well or to at rate. data those we're how well TSSXX, to XX% durability TSS SVR durability presenting is a as what a see very and response as physicians XX% And is of as both we've the SVR last. a that's endpoints. both

patients again, evidence that the suggest And remains progression evaluate comparator, But focus right SVR none this In look as as experienced well that TSSXX. question the efficacy this to week off myelofibrosis. study as at fact, as are mentioned, you endpoints to could JAK the patients to your on much to XX. just The SVR, a at the data or about population.In who of for regards as patient body we'll be This part TSSXX of cut it are our of this multiple other for either durability game-changer continue of that ruxolitinib. now. still upon relevant really combination very Phase would, appropriate August continue is III X, build of we'll a naive radiographic

naive patients ruxolitinib for XXX. care the who standard So is platelet of are who counts have JAK myelofibrosis above

design the well question evaluates, with data study of about question. enthusiastic the the this standard specifically So is Very appropriate and as I/Phase current of terms to care.In study. relative from about great Phase the again, eltanexor, combination those efficacy II your observed

of median X poor to right, the specifically evaluating are encouraging, X patient patients, this have I population, very the months. XX-month seen II patient relapsed survival and refractory disclosed previously, MDS around that as We And we've Phase higher eltanexor as in we've is to been very hard-to-treat part survival. overall X- overall both Phase population survival in risk a very

this are everybody QX forward optimizing and updating around in program, probably next of steps We look the to our call. the process in

Operator

there a ma'am? up, follow Was

Shea Feeney

it. That's

Operator

The with next Maury comes Raycroft question from Jefferies.

Maurice Raycroft

Congrats on going was to endometrial. the progress. I one ask on

how of So think could any separately, do you survival XPORT for then the the show wild-type study? anti-PDX III on data are with SIENDO the III initial Phase And If when overall upfront? TPXX many also how can enrolling? you and sense a maintenance Phase from have provide in you therapy patients selinexor as patients chemo perspective getting And do you is endometrial, that? the

Reshma Rangwala

question. Maury. great Yes,

you know, So as continue so we survival. follow overall to

very excited. are We

to survival to for presenting maintenance. by going and are more trials for call, patients from of in I watch proficient more not the year, The in of have who are addition so the in as of to they come data minority are as question time patients on PXX at progression-free there.In that their come overall months. MMR over approval in is chemotherapy a patients do standard only represent are followed so pMMR dostarlimab wait. to chemotherapy, MMR be Keep there dostarlimab with XX%. with inhibitors combination the the as a is remain it by the the mind new TPXX in followed a continues in the well standard care, the chemotherapy some around mentioned later key who deficient, remaining only the We PDX combination couple to this first so of specifically from survival, wild-type new the Obviously, endpoint SIENDO next subgroup terms is

Maurice Raycroft

and Got commercial. perspective And helpful. how going? also wanted into any it. that's a enrollment ask That's other multiple myeloma then separate on question to And

was line there versus line second were said in patients these Can on XX%. growth give You color line later approximately new early evolved, when XX% were starts. you setting? in have you repo some line rates specifically fourth year-over-year just us There the in to how

Richard Paulson

just it myeloma. the to progress follow-up Yes. turn the Reshma? question, Sohanya I'll trial Reshma Maybe and in to on on multiple

Reshma Rangwala

Thank you.

largely the to because that care. active in I already are again, ago translating highlighted doesn't think is and is, standard trials, study. sites insights patient we weeks demonstrating data. benefit the enrollment need a enthusiasm have lot enthusiasm patients new onto lot of enrollment from activation unmet we, couple and a high these XX plus the just is that at So of population are that a clinical and most That There's our in onto fact, that enrolling around to well. -- in And have largely that's a going recently was the Spain, ESMO due of

is study proceeding the nicely. going So it's quite --

Richard Paulson

Sohanya?

Sohanya Cheng

around XX% address And I growth. year-over-year the can question

when So of QX is or year-over-year mix look the fourth growth. XPOVIO our new that of XX% a you represents XX% line, over in starts, which in second at

out, lines, Now pointed benefit is for the driver the huge you us, that growth because of a duration primarily into we earlier shift of as see.

multiple largely our refills. lines duration duration we the discussed dose be But time And nice we've in management choppy, Now on by the also earlier of we increasing therapy we driven can think therapy patient data and takes and is better trend are mature. upward patients this sources, as this a data the about previously, supportive to triangulate on as care. and data of as lower seeing of

Operator

comes question Kusy [Operator Instructions] The from Colleen with Baird. next

Colleen Hanley

on one myeloma. a First multiple

I recommendation could With a the for the you can the And of to year? through us help Category of be that then of have guideline how elevation the much XVd X, understand follow-up. a tailwind NCCN end

Richard Paulson

take one? you can Sohanya, that

Sohanya Cheng

Yes. Thanks, Colleen.

become landscape as think as foundational we a about competitive XPOVIO established evolving So mechanism. myeloma, in multiple the has

in Category recommended Now from meaningful, this setting treatment where driver particularly be of to X, decisions. regimens a used of elevation regimens preferred and X other is Category large to the now XPOVIO it's which from community

NCCN that impact, X One class X So the I Velcade an against XPOVIO, preferred impact to novel going as XPOVIO were we of of guidelines favorable switching and like notably, see not the into well are therapy was updates elevation the recommending terms dex made for mentioned. as Category XPOVIO status.In of as supports class a overnight.

However, with And multiple over growth we myeloma, it is an area that time. is sensitive. highly steady see promotionally

excited we position actively the field this able and our lines. update in we team strengthens this that believe our are earlier is in promote to community and forward. moving today now the So And

Colleen Hanley

specified results endometrial, then pre dostarlimab this for helpful. Phase dMMR study? in the the evolution and and given of the with for And pMMR. any ongoing you're pMMR Have and analysis population treatment used That's of PXX sort really encouraging landscape III wild-type patient

Reshma Rangwala

Yes, question, Colleen. great

at It's stratification SIENDO, vast majority represent do Phase going we'll will a assume given specifically the be we of to to patients III MMR these as the pMMR specifically our that looking ongoing they be are XX% again, factor, which similar not versus balance across in had subgroups. endpoints, dMMR efficacy X MMR to that at we continue proficient So the the ensure fact that'll But we in that well. likely. looking

Operator

comes question next Joseph The JPMorgan. from Eric of

Detlef Winckelmann

Detlef us BMS one from with on Eric. be the is for Quick just This on the drug could combination mezigdomide.

thoughts overall what selinexor? in there with combination on the is, the terms Just rationale of

Reshma Rangwala

really Absolutely a great about question. novel We're combination. excited really, this

Cancer our just upon out Dana-Farber Just Institute, of already to this insight, this number remarkable bit of give multiple combinations efficacy patients builds some specifically in myeloma. selinexor has was of KOLs a thought combination shown with of coming Richardson. right, He by Paul that key the that little you pushed

of novel therapies more myeloma a the given combination, resistance CELMoD gives into really myeloma for to patients. and reverse myeloma drugs becoming that other these more selinexor potentially are as they and combination individually can for that resistance. with mezigdomide T-cell well of introducing shown important of this sequencing both T-cell BMS, him, is inhibition fact that this now multiple and of the multiple XPOX fact to This has The And potentially multiple is treaters, these of as important T-cell tool in course, but arsenal. also in help concept course, us aspect them is, with it the that therapies intriguing novel their

Detlef Winckelmann

And mind then of Medicare design the of just in going of and the wanted to a quickly then XXXX? And Patient see D affect Assistant helpful. forward? how impact closures this kind be That's on Program the might we kind Part foundation

Sohanya Cheng

you for thank can I take the question. Yes, that.

we as free increased saw PAP closures. So year we drug utilization an this of terms in know, -- due to foundation of

million million to has PAP in the million through of impact which $X million, QX, year-to-date been to impact roughly $X about $X a PAP Now $X QX. includes

the Now X there we in PAP, starts the in as QX, refill impact patient a but new result of foundations open normalized, and saw were that -- were remained.

where foundation similar foundations X QX, of the as the as into Now it PAP we X QX date. change requirements, less anticipate X% to change.Now we coinsurance dynamic Medicare was Part not by copay expect Program of encouraged to of the very patients in QX open patient significantly being eliminates move the does in need the the we which therefore, remain the for Patient these And we assistance. are design impact XXXX, assuming forward in these the Assistance beneficiary D to utilize IRA-related for burden our and

Operator

back turn [Operator to Richard any like remarks. for This over Paulson I question-and-answer session. closing would our to the Instructions] concludes conference

Richard Paulson

that well are capabilities. our late-stage myeloma our Thank of mentioned, as as operator, expected continue prepared in Phase X to today.As you, with joining as out have investments rapidly on the of we to foundation long-term continue we read wonderful a to development 'XX multiple we proven day. you us everyone, and stakeholders.Thank advance 'XX we we commercialization our And for III you, our and expand for to pipeline, value near- and are growth all of create work thank and concentrating for for through programs joining, stage next

Operator

now concluded. conference today's The presentation. for Thank attending has you

You disconnect. may now

Karyopharm Therapeutics (KPTI) 2 Nov 232023 Q3 Earnings call transcript